Biomarkers play a critical role in the field of vaccine immuno-oncology, where they help track the immune system’s response to cancer vaccines. Cancer vaccines aim to stimulate the body’s immune system to target and destroy cancer cells. Biomarkers in this context serve as measurable indicators of how well the immune system is reacting to the vaccine. These markers can include specific proteins, genetic alterations, or immune cell signatures that reveal the presence of immune activation. By identifying these biomarkers, researchers can assess the effectiveness of cancer vaccines, predict outcomes, and tailor therapies to individual patients for more personalized treatment strategies. The identification of robust biomarkers not only aids in the early detection of treatment success but also provides insights into the mechanisms of immune resistance, helping improve the design of future cancer vaccines for better patient outcomes.
Submit your abstract Today
